New Virus-Based COVID booster enters human trials
NCT ID NCT05389319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new COVID-19 booster vaccine called Prime-2-CoV_Beta, made from a modified orf virus. It involves 96 healthy adults aged 18-55 who have already been vaccinated or infected. The main goal is to check safety and how well the vaccine boosts the immune system.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Prime-2-CoV_Beta (a vaccine made from a modified orf virus to boost immunity against COVID-19)
What this could lead to
If successful, this could provide a new type of COVID-19 booster that may offer broader or longer-lasting protection.
What could go wrong
This is an early, small trial (96 people) focused on safety and immune response, not on preventing infection. The vaccine may not work as hoped or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bernhard-Nocht-Institut für Tropenmedizin
Hamburg, Free and Hanseatic City of Hamburg, 20359, Germany
-
University Hospital Tübingen, Institute of Tropical Medicine
Tübingen, Baden-Wurttemberg, 72074, Germany